SCHEMBL208629

SCHEMBL208629

Cn1ccc(O)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30695162 0.71 KMT2A (0.44)
SCHEMBL21465403 0.70 KMT2A (0.43)
Lithium SCHEMBL31401899 0.69 JMJD6 (0.42)
SCHEMBL1630090 0.69
SCHEMBL324166 0.69
SCHEMBL30463448 0.68 KDM4E (0.44)
SCHEMBL31277599 0.68 JMJD6 (0.49)
SCHEMBL350714 0.67
SCHEMBL6183796 0.67
SCHEMBL20892184 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 499 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140294763-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2014-10-02 US claimed
EP-2368877-B1 Peptidomimetic protease inhibitors and intermediates for their preparation As treatment for HCV infection VERTEX PHARMA (US) 2014-05-07 EP claimed
EP-1958956-B1 Peptidomimetic protease inhibitors VERTEX PHARMA (US) 2013-12-11 EP claimed
US-20120282219-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-11-08 US claimed
US-8252923-B2 Peptidomimetic protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-28 US claimed
CN-102504014-A Peptidomimetic protease inhibitors LILLY CO ELI 2012-06-20 CN claimed
EP-1990343-B1 Azaindoles AVENTIS PHARMA LTD (GB) 2012-04-04 EP claimed
US-20120064034-A1 Peptidomimetic protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-15 US claimed
EP-2368901-A1 Peptidomimetic protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-28 EP claimed
EP-2368877-A1 Chiral intermediates for the preparation of peptidomimetic protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-28 EP claimed
EP-1778228-A2 THERAPEUTIC COMPOUND AND TREATMENTS Medisyn Technologies, Inc. (US) 2007-05-02 EP claimed
EP-1027328-B1 SUBSTITUTED ANILIDES AVENTIS PHARMA LTD (GB) 2006-08-23 EP claimed
WO-2006010127-A2 THERAPEUTIC COMPOUND AND TREATMENTS MEDISYN TECHNOLOGIES, INC. (US) 2006-01-26 WO claimed
US-20060014770-A1 Inhibiting cell growth including cancer such as leukemia, melanoma, cancer of non-small cell lung, colon , CNS, ovarian , renal , prostate , breast , and pancreas COUSINEAU, HENRY 2006-01-19 US claimed
US-20050197299-A1 Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives VERTEX PHARMACEUTICALS INCORPORATED 2005-09-08 US claimed
EP-0960096-B1 SUBSTITUTED BETA-THIOCARBOXYLIC ACIDS AVENTIS PHARMA INC (US) 2005-04-06 EP claimed
EP-1486486-A2 Substituted B-thiocarboxylic acids Aventis Pharmaceuticals Inc. (US) 2004-12-15 EP claimed
EP-1189883-B1 SUBSTITUTED PYRROLIDINES AS CELL ADHESION INHIBITORS AVENTIS PHARMA LTD (GB) 2004-11-03 EP claimed
EP-1259495-B1 INDANE DERIVATIVES AND THEIR USE AS CELL ADHESION INHIBITORS AVENTIS PHARMA LTD (GB) 2004-09-22 EP claimed
EP-1140916-B1 HETEROARYL-CYCLIC ACETALS AVENTIS PHARMA LTD (GB) 2002-11-13 EP claimed